Jonathan Goodman, MPhil

For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.

Patients living in states with lower eligibility limits had worse survival rates, regardless of cancer stage at diagnosis.

This is the first phase 3 study to validate LAG-3 inhibition as a therapeutic strategy in cancer, according to an investigator.

The median DFS was not reached in the atezolizumab group and was 37.2 months in the best supportive care group.

Secondary end points were not significantly different between the 2 groups, including overall survival.

Tazemetostat demonstrated preclinical activity against EZH2­-mutant non-Hodgkin lymphomas.

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.

Researchers explored whether adding trastuzumab to carboplatin and paclitaxel would improve survival outcomes for patients with advanced/recurrent disease with overexpressed HER2/neu.

The US FDA has approved a consumer test that may indicate increased breast and ovarian cancer risk in some individuals.